SCHEMBL4044207

SCHEMBL4044207

CCOC(=O)NNC

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL355253 0.86 GAA (0.55)
SCHEMBL18048520 0.81
SCHEMBL11031342 0.80
SCHEMBL11651480 0.79 LMNA (0.48)
SCHEMBL28604705 0.79 LMNA (0.48)
SCHEMBL154280 0.79 GAA (0.53)
SCHEMBL9825086 0.78 LMNA (0.44)
SCHEMBL42229 0.78
SCHEMBL8944774 0.77 ALDH1A1 (0.50)
SCHEMBL250456 0.77

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3889154-A1 HETEROCYCLIC COMPOUND INTERMEDIATE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF Wuhan LL Science And Technology Development Co., Ltd. (CN) 2021-10-06 EP disclosed
WO-2021028806-A1 HETEROCYCLIC WDR5 INHIBITORS AS ANTI-CANCER COMPOUNDS NOVARTIS AG (CH) 2021-02-18 WO disclosed
WO-2021026672-A1 HETEROCYCLIC WDR5 INHIBITORS AS ANTI-CANCER COMPOUNDS NOVARTIS AG (CH) 2021-02-18 WO disclosed
WO-2020157652-A2 CDK2 INHIBITORS PFIZER INC. (US) 2020-08-06 WO disclosed
WO-2019014315-A1 RAD51 INHIBITORS CYTEIR THERAPEUTICS, INC. (US) 2019-01-17 WO disclosed
US-9847229-B2 Method for forming a semiconductor device and semiconductor device INFINEON TECHNOLOGIES AG (DE) 2017-12-19 US disclosed
US-9526648-B2 Intragastric device for treating obesity SYNERZ MEDICAL, INC. (US) 2016-12-27 US disclosed
US-20160287114-A1 NEUROMODULATION SYSTEMS HAVING NERVE MONITORING ASSEMBLIES AND ASSOCIATED DEVICES, SYSTEMS, AND METHODS MEDTRONIC ARDIAN LUXEMBOURG S.A.R.L. (LU) 2016-10-06 US disclosed
CN-102695545-B Compositions comprising enzymatically cleavable ketone-modified opioid prodrugs and optional inhibitors thereof 特色疗法股份有限公司 2016-08-17 CN disclosed
US-20160163177-A1 Water Use/Water Energy Use Monitor and/or Leak Detection System KLICPERA MICHAEL EDWARD (US) 2016-06-09 US disclosed
US-6200935-B1 FOR CONTROLLING UNDESIRABLE PLANTS BAYER AKTIENGESELLSCHAFT (DE) 2001-03-13 US disclosed
US-6162765-A Substituted N-aryl nitrogen-containing heterocyclic compounds BAYER AKTIENGESELLSCHAFT (DE) 2000-12-19 US disclosed
EP-1051414-A1 SUBSTITUTED HETEROARYLMETHYL COMPOUNDS USED AS HERBICIDES Bayer Aktiengesellschaft (DE) 2000-11-15 EP disclosed
WO-1999038861-A1 SUBSTITUTED HETEROARYLMETHYL COMPOUNDS USED AS HERBICIDES BAYER AKTIENGESELLSCHAFT (DE) 1999-08-05 WO disclosed
EP-0797573-A1 3-ARYL-1,2,4-TRIAZOLE DERIVATIVES WITH HERBICIDAL PROPERTIES BAYER AG (DE) 1997-10-01 EP disclosed
WO-1996018618-A1 3-ARYL-1,2,4-TRIAZOLE DERIVATIVES WITH HERBICIDAL PROPERTIES BAYER AKTIENGESELLSCHAFT (DE) 1996-06-20 WO disclosed
EP-0640594-A1 Hydantoin derivative as metalloprotease inhibitor FUJIREBIO INC. (JP) 1995-03-01 EP disclosed
EP-0553594-A1 Polymeric thermoplastic materials, comprising 1,2,4-triazolidine-3,5-dione derivatives as stabilisers CIBA-GEIGY AG (CH) 1993-08-04 EP disclosed
US-5196465-A Heat resistance CIBA-GEIGY CORPORATION (US) 1993-03-23 US disclosed
US-4076938-A Process for the production of 3-hydroxy-1,2,4-triazole derivatives CIBA-GEIGY CORPORATION (US) 1978-02-28 US disclosed